🔗 Share this article

Elected officials have raised concerns that the United Kingdom's negotiated accords with the US administration are "lacking a solid foundation." This stems from revelations that a so-called "milestone" deal on drug pricing, which pledges zero tariffs in exchange for the NHS increasing its costs, lacks any underlying contract beyond vague headline terms outlined by government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, promoted as a "landmark" achievement, remains an "broad understanding" without formal ratification. Observers point out that the public statements from the UK and US governments frame the deal in markedly contrasting terms. The British version focuses on securing "duty-free access" as a unique achievement, while the American announcement concentrates on the agreement for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has promised concessions to increase medicine costs in return for only a assurance from President Trump," stated David Henig, a trade policy analyst. "We know he has a tendency for not keeping promises."

A Pattern of Unreliability

Anxieties have been heightened by Washington's recent decision to suspend the major technology agreement, which was previously called "a huge leap forward" in the bilateral relationship. The US claimed a insufficient movement from the UK on reducing other tariffs as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an earlier tariff deal have still not been formally ratified by the US, despite a fast-approaching January deadline. "It is our belief that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

In confidential discussions, ministers have admitted unease that the government's deals with Washington are flimsy and unreliable. One minister described the series of agreements as "resting on shaky ground," while another described the situation as the "current reality" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, argued: "What is even more astonishing than the administration's tactics is the UK government's optimistic assumption that his administration is a trustworthy negotiator. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Officials have downplayed the possibility of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it less abstract than the paused tech deal.

Officials admit that unpredictability is inherent in dealing with the Trump administration. However, they argue that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, problems have emerged in implementing the broader trade deal. Promised quotas on beef exports have yet to be finalized, and the commitment to "eliminate duties on UK metals" has is still pending, with tariffs remaining at 25%.

As negotiations continue, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.